Skip to search formSkip to main contentSkip to account menu

Low Molecular Weight Cyclin E

Known as: LMW-E 
Proteolytically processed forms of cyclin E proteins, which are specifically generated in tumors that overexpress cyclin E proteins.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cytoplasmic Cyclin E is an Early Event for Progression to Invasive Breast Cancer
  • 2017
  • Corpus ID: 52253422
As depicted in this figure, we have discovered that the LMW-E isoforms are potent oncogenes that act early in the etiology of… 
2016
2016
Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer
Deregulation of the cell cycle machinery is a hallmark of most cancers, making the positive regulators of cell cycle such as… 
2015
2015
Abstract 3171: IL-25/IL-17E does not induce breast tumor cell apoptosis and both IL-17A and IL-25/IL-17E contribute to breast cancer survival and proliferation associated with generation of pro…
Pro-inflammatory IL-17 cytokines were initially described for their pathogenic role in chronic inflammatory diseases and… 
2015
2015
Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Deregulation of the cell cycle machinery is a… 
2015
2015
Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers
Deregulation of the cell cycle machinery is a hallmark of breast cancer, facilitating aberrant proliferation that fuels… 
2015
2015
Abstract 3772: Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer
Purpose: While we know that many cytotoxic chemotherapeutic agents act to modulate the cell cycle, the role of cyclin E as a… 
2014
2014
A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer.
163 Background: Low molecular weight cyclin E (LMW-E) isoforms are overexpressed in a majority (~70%) of triple-negative breast… 
2013
2013
Abstract P6-12-09: Targeting deregulated cyclin E in inflammatory breast cancer via sequential combination therapy
Inflammatory breast cancer (IBC) is a rare, highly aggressive form of breast cancer, accounting for 2-5% of all breast cancers in… 
2012
2012
Too Much Cleavage of Cyclin E Promotes Breast Tumorigenesis
Cyclin E, together with cyclin-dependent kinase 2 (CDK2), functions as a gatekeeper to promote G1/S transitions and the… 
2011
2011
P5-03-01: Cytoplasmic Cyclin E and P-CDK2 Expression in Triple Negative Breast Carcinomas Measured by Immunohistochemistry Correlates with Poor Outcome.
Background: Triple negative breast carcinomas (TNBCs) are aggressive malignancies that lack effective therapeutic targets but… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)